Fluicell

Fluicell FCF per Share

The Free Cash Flow per Share of Fluicell (FLUI.ST) as of Nov 20, 2026 is -7.20 SEK. In the previous year, Free Cash Flow per Share was -13.95 SEK — a change of -48.38% (higher).

FCF per Share

-7.20SEK

YoY

-48.38%

Last updated:

Free Cash Flow per Share of Fluicell is 2025 -7.20 SEK. Free Cash Flow per Share of Fluicell was 2024 -13.95 SEK. It decreases by -48.38% higher compared to the previous year.

The Fluicell FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-46.82 SEK
Jan 1, 2019
-59.72 SEK
Jan 1, 2020
-37.31 SEK
Jan 1, 2021
-36.42 SEK
Jan 1, 2022
-0.24 SEK
Jan 1, 2023
-25.01 SEK
Jan 1, 2024
-13.95 SEK
Jan 1, 2025
-7.20 SEK
The Fluicell FCF per Share history
YEARFCF per ShareYoY
-7.20SEK-48.38%
-13.95SEK-44.23%
-25.01SEK+10,186.77%
-0.24SEK-99.33%
-36.42SEK-2.40%
-37.31SEK-37.52%
-59.72SEK+27.55%
-46.82SEK-56.33%
-107.22SEK+174.58%
-39.05SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

Free Cash Flow per Share of Fluicell is -7.20 SEK in 2025.

Free Cash Flow per Share of Fluicell changed from -13.95 SEK to -7.20 SEK, representing a -48.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Fluicell since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Fluicell

All Key Metrics — Fluicell